Full-Time

Director, Global Clinical Development

Updated on 8/18/2026

Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharma maker of Abilify

Compensation Overview

$209.6k - $313.4k/yr

+ Incentive opportunity

Princeton, NJ, USA

Hybrid

The role is based in the Princeton or Rockville office and requires international travel approximately 30% of the time, including weekends.

PharmD, PhD, MD, Doctor of Osteopathic Medicine (DO), Doctor of Dental Surgery (DDS)

Category
Biology & Biotech (1)
Required Skills
Market Research
Word/Pages/Docs
Biostatistics
Marketing
Excel/Numbers/Sheets
Microsoft Outlook

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Requirements
  • A clinician with a Doctor of Medicine or Doctor of Osteopathic Medicine degree is required; psychiatrists or neurologists are preferred, and exceptional candidates with other specified clinical or scientific doctorates may be considered when complemented by a team or consulting clinician.
  • At least 6 years of experience in the pharmaceutical industry or academic translational clinical research is typically required, depending on the type of experience.
  • Prior management experience, either direct or indirect, is preferred for the clinical leadership profile.
  • The role requires thorough knowledge of clinical medicine and science management.
  • The role requires effective communication in meetings and written and oral presentations, including proficiency with Microsoft Word, Excel, PowerPoint, and Outlook.
  • The role requires an advanced understanding of drug development principles and clinical trial implementation, management, and reporting.
  • The role requires working knowledge of biostatistics, clinical pharmacology, formulation science, data management, and medical writing.
  • The role requires complete understanding of global regulatory requirements.
  • The role requires working knowledge of health value creation, including financial assessment, project planning and budgeting, market research, and commercialization strategies.
  • The role requires willingness to travel 30% of the time, including weekends, and ability to travel internationally.
Responsibilities
  • Design and oversee clinical research programs and protocols for OPDC products under good clinical practices.
  • Evaluate and lead clinical development of central nervous system and Digital Medicine products at different stages of development for a global health-care market.
  • Consult with patients or their representatives, clinical, regulatory, and scientific leaders, and apply their recommendations to optimize trial objectives, designs, and protocols.
  • Develop focused expertise and serve as an internal medical and scientific consultant to health economics, medical affairs, marketing, regulatory, statistical, and other research project teams, as well as external regulatory agencies.
  • Author global development and commercialization plans and oversee trials that determine the clinical safety, efficacy, medical usefulness, and value of drug or medical device candidates.
  • Interpret and communicate results of Phase I through Phase IV investigations in preparation for a new drug.
  • Act as signatory on new drug application submissions and clinical study and safety documents.
  • Contribute to product life-cycle management from the earliest stages of development and identify innovations that strategically add value.
  • Provide strategic oversight of vendor and contract research organization relationships and clinical input to their governance committees.
  • Lead and support regulatory filing activities and documents, providing strategic direction and editing for concise, clear, and convincing communications.
Desired Qualifications
  • Experience as a psychiatrist or neurologist.
  • Supplementary Ph.D., Master of Public Health, or Master of Business Administration degree.
  • Experience leading, managing, and motivating internal staff, external investigators, or consultants.
  • Experience working across different therapeutic areas and stages of clinical development.
  • Experience with successful regulatory filings.
  • Experience applying financial assessment such as net present value, project planning and budgeting, market research, and commercialization strategies.
Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Otsuka closed Transcend in June 2026, expanding psychiatry beyond Abilify dependence.
  • DAWNZERA gained EU authorization in January 2026, opening paid sales across 27 countries.
  • Paradise uRDN and CART BP pro broaden Japan's hypertension platform and device distribution.

What critics are saying

  • SIMTRIYO waits on DEA scheduling, delaying revenue until late 2026.
  • VOYXACT's accelerated approval depends on confirmatory kidney-outcome data; failure risks withdrawal.
  • Transcend's TSND-201 PTSD program remains clinical-stage, risking a $1.225 billion write-down.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs CNS, nephrology, and device assets across Japan, US, and Europe.
  • SIMTRIYO gives Otsuka a first-in-class ADHD stimulant franchise after July 2026 FDA approval.
  • DAWNZERA and VOYXACT anchor rare-disease pipelines with global reimbursement and accelerated paths.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.